Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
Clinical trial NCT07230314 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07230314
- Sponsor
- Jinling Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-30
- Primary completion
- 2026-11-30
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.